The woman had a disorder called hypertrophic obstructive cardiomyopathy (HOCM). Ramos sat across from the patient with a model of the heart and a pad of paper to help him show how this small ...

Hypertrophic obstructive cardiomyopathy (HOCM) is the most common genetic heart disease, affecting about 1 in every 500 people, according to the American Heart Association (AHA). In people with ...

Mavacamten (Camzyos) is the first ever drug to be approved for HOCM found to improve symptoms and may reduce the need for surgery for some people. On April 28, the U.S. Food and Drug ...

Approximately 70 percent of patients with HCM will develop hypertrophic obstructive cardiomyopathy (HOCM). This condition occurs when the thickened septum blocks blood flow through the heart. The ...

"And we were given a diagnosis of HOCM, which is a malady of the heart, which enlarged the walls in his heart and didn't allow his heart to appropriately pump blood to his organs." On Saturday ...

Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The most important use of the Valsalva maneuver is to distinguish the murmur of aortic stenosis from hypertrophic obstructive cardiomyopathy — or simply to bring forth the murmur of HOCM.

Hypertrophic obstructive cardiomyopathy (HOCM) is a pathologic cardiac condition in which the interventricular septum is abnormally thickened. The classic finding in HOCM is large dagger-like ...

In April of 2022, FDA approved Bristol Myers Squibb’s (BMS) Camzyos (mavacamten), the first treatment to target and inhibit cardiac myosin, the underlying protein involved in hypertrophic obstructive ...